Key Highlights
- $700M investment marks Roche’s first East Coast US manufacturing site, part of a $50B commitment to US R&D and infrastructure
- Facility to create more than 1,900 jobs and boost capacity for next-generation metabolic medicines, including obesity treatments
- Project designed with advanced automation, digital capabilities, and sustainability to ensure resilient global supply chains
Strategic Expansion into US Manufacturing
Genentech, Roche’s US subsidiary, has broken ground on a new $700M state-of-the-art manufacturing site in Holly Springs, North Carolina. This site is Roche’s first East Coast facility and a key milestone within the group’s $50B long-term investment strategy in US manufacturing, infrastructure, and R&D.
Focus on Next-Generation Metabolic Medicines
The 65,000 m² facility will specialize in producing Roche’s future pipeline of metabolic medicines, with a strong focus on next-generation obesity treatments. By leveraging advanced biomanufacturing and automation, Roche aims to accelerate patient access to life-changing therapies.
Economic and Workforce Impact
The project will generate more than 1,900 jobs, strengthening North Carolina’s growing role as a US biopharma hub. The choice of Holly Springs was driven by its skilled workforce, academic ecosystem, and proximity to leading life sciences clusters.
Sustainability and Global Supply Chain Resilience
Designed for high-volume and efficient production, the site incorporates modern digital technologies and sustainable practices. With additional space for future expansion, the facility complements Roche’s global network, ensuring supply resilience for patients worldwide.
About Roche
Roche is the world’s largest biotechnology company and the global leader in in-vitro diagnostics. Founded in 1896, Roche develops innovative medicines and diagnostics in oncology, neuroscience, and metabolic diseases. Headquartered in Basel, Switzerland, Roche integrates data-driven personalized healthcare with a strong commitment to sustainability, aiming for net zero emissions by 2045.
About Genentech
Genentech, founded in 1976 and based in South San Francisco, is a pioneering biotechnology company and a wholly owned subsidiary of Roche. Genentech discovers, develops, and manufactures medicines for serious and life-threatening conditions, and serves as Roche’s innovation engine in the US market.
By